Aims/hypothesis The aim of this study was to examine the effect of cord blood autoantibodies on the risk for type 1 diabetes in children followed prospectively from birth. Methods The Diabetes Prediction in Skåne (DiPiS) study consists of 35,853 children from the general population born during 2000-2004. Samples were collected at birth and analysed for HLA genotypes and autoantibodies to glutamate decarboxylase 65 (GAD65), insulin and insulinomaassociated protein 2 (IA-2). After adjusting for HLA, sex, maternal age and parental type 1 diabetes, independent associations with risk of diabetes were assessed using multivariate Cox proportional hazards models. Results In total, 151 children (0.4%) had developed type 1 diabetes by the end of 2013 at a median age of 5.8 years (0.8-12.2 years). In the multivariate analysis, the presence of IA-2 autoantibodies (IA-2A) in cord blood (HR 6.88, 95% CI 1.46,32.4; p=0.003), but not maternal diabetes (HR 1.38, 95% CI 0.24,7.84; p=0.71), was associated with risk of developing type 1 diabetes. No increased risk could be seen for the presence of autoantibodies to GAD65 or insulin. Conclusions/interpretation Our study indicates that the presence of cord blood IA-2A superimposes maternal diabetes and other cord blood islet autoantibodies as a predictor of type 1 diabetes development in the child. These findings may be of significance for future screening and study protocols on type 1 diabetes prediction.
Introduction
Early prediction of type 1 diabetes is crucial in the attempts at preventing or stalling the disease. Identifying risk factors for islet autoimmunity and factors accelerating the autoimmune process will enable more successful study enrolment and treatment attempts.
Islet autoantibodies are found in 3-5% of cord blood samples from newborns in the general population [1] , with an even higher proportion found, as expected, in offspring of mothers with type 1 diabetes [2] . Previous studies, mainly recruiting children with first-degree relatives with type 1 diabetes, have investigated the significance of cord blood autoantibodies with contradictory results [3, 4] .
As only 10-13% of newly diagnosed children and young adults with type 1 diabetes have a first-degree relative with the disease it is difficult to make predictions for the general population based on analyses of these subgroups. In the Diabetes Prediction in Skåne (DiPiS) study, children from the general population are followed from birth with the aim of identifying risk factors and predictive markers of type 1 diabetes. In the present study we had the opportunity to examine the impact of cord blood autoantibodies on risk of type diabetes.
Methods

Study population and participants
In the southernmost part of Sweden, cord blood of children born between September 2000 and August 2004 was analysed for HLA-DQ genotypes, glutamate decarboxylase 65 autoantibodies (GADA), insulin autoantibodies (IAA) and insulinoma-associated protein 2 autoantibodies (IA-2A) in the DiPiS study [5] . When the child reached 2 months of age the parents were asked to fill out a written consent form and a questionnaire regarding family history of diabetes, birthweight, gestational age and perinatal infections [5] . The study protocol and collection of data are illustrated in ESM Figure 1 .
By the end of 2013, the DiPiS cohort had reached 9-13 years of age and 151 children had been diagnosed with type 1 diabetes. New patients are registered via the Better Diabetes Diagnosis (BDD) study, covering an overwhelming majority of new diabetes cases in Sweden. The regional ethics review board in Lund, Sweden approved the study.
HLA genotyping HLA was analysed on dried blood spot (DBS) filters as described in detail elsewhere [6] . In the current analysis, HLA was classified as HLA-DQA1*0501-DQB1*0201 (DQ2) or HLA-DQA*0301-DQB1*0302 (DQ8) and stratified into the following four risk groups: (1) DQ 2/8; (2) DQ8/8 or 8/X; (3) DQ2/2 or 2/X; (4) DQ X/X (X is neither DQ2 nor DQ8).
Cord blood autoantibodies DBS eluates were incubated with labelled antigen to GAD65 and IA-2, and autoantibody-bound labelled antigen was separated from free with Protein A-Sepharose (Amersham Biosciences, Uppsala, Sweden). Positive samples (combined GADA and IA-2A analysis >99th percentile) were reanalysed in separate assays for GADA and IA-2A. IAA was screened in serum in a microassay. All samples above the 99th percentile were reanalysed to correct for nonspecific binding. The exact procedure has been described elsewhere [7] .
Statistical methods Statistical analyses were performed using SPSS (version 21, SPSS, Chicago, IL, USA) and R version 3.03 using the survival package (R Core Team [2014] R Foundation for Statistical Computing, Vienna, Austria). HRs with corresponding 95% CIs, as estimated by univariate Cox proportional hazards models, were used to identify factors with significant influence on risk of type 1 diabetes in the child. A multivariate Cox proportional hazards model tested for an independent association of each autoantibody with the child's diabetes risk while also adjusting for HLA-DQ, sex, maternal age and parental type 1 diabetes. A separate baseline hazard was fitted for each HLA risk group. HRs for HLA genotype were calculated in a multivariate model without stratification. Multivariate analysis included the following variables: cord blood IA-2A, IAA and GADA (categorised as positive if above the 99th percentile, treated as categorical variables), gestational week, relative birthweight percentile, infection during pregnancy, HLA risk group, sex, maternal and paternal type 1 diabetes, and mother's age at delivery.
Results
Baseline characteristics A total 35,683 cord blood samples were collected in 48,058 children born during the study period. Parents of 25,392 children returned the 2-month questionnaire. Of the responders to the questionnaire, 190 children had a mother with type 1 diabetes and 985 had gestational diabetes. Paternal type 1 diabetes was reported in 285 of children (ESM Table 1 ). As of 31 December 2013, 151 children had been diagnosed with type 1 diabetes with a median age at diagnosis of 5.8 years (0.8-12.2 years). In total, 12 children had a parent with type 1 diabetes (8%); eight fathers and four mothers. Autoantibody status and demographics at diagnosis are shown in (ESM Table 1 ).
Autoantibodies in cord blood and their influence on T1D risk Autoantibodies against GAD65, IA-2 and insulin were found in 295 (0.8%), 78 (0.2%) and 509 (1.4%) cord blood samples, respectively. A total of 44 samples (0.1%) were positive for both IA-2A and GADA, and 25 samples (0.07%) were triple positive. Contingency tables with autoantibody status and overlap with maternal type 1 diabetes are shown in ESM Tables 2-4. In children of diabetic mothers the presence of IA-2A in cord blood was associated with increased risk for the development of type 1 diabetes in the child (Fisher's exact test p=0.037; ESM Table 2 ). However, in children with IA-2A present in cord blood the presence of diabetes in the mother was not associated with the development of type 1 diabetes in the child (Fisher's exact test p=1; ESM Table 3) .
In a multivariate model with autoantibodies and parental type 1 diabetes included, only IA-2A was a predictor of the child's risk for the development of diabetes. The risk was significant in both a univariate model (HR 14, 95% CI 5.0,37; p<0.001) and a multivariate model (HR 6.4, 95% CI 1.8,22; p=0.003) (Fig. 1) . GADA and IAA alone showed evidence of association with risk of type 1 diabetes, but not after adjustment for maternal type 1 diabetes status at birth (GADA HR 1.5, 95% CI 0.5,4.8; p=0.48; IAA HR 1.1, 95% CI 0.4,3.4; p=0.82; Table 1 ).
HLA-DQ derived risk and parental diabetes The risk profile with HLA_DQ genotypes was similar to that of previous studies (Table 1) .
Having a father with type 1 diabetes was associated with an increased risk for the development of diabetes in the child (HR 3.4, 95% CI 1.6,7.0; p<0.001). Maternal diabetes was associated with the child's risk of developing type 1 diabetes (HR 3.5, 95% CI 1.3,9.5; p=0.014) but not after adjusting for the presence of IA-2A (HR 1.6, 95% CI 0.3,7.0; p=0.60; Table 1 ).
Discussion
In this population-based prospective study, we report that the presence of IA-2A in cord blood increases the risk for the development of type 1 diabetes in the child, and this risk seems to be unrelated to the diabetes status of the mother.
It has been well established that islet autoantibodies, and specifically IA-2A, measured during childhood predicts the [1, 8, 9] . Moreover, the maternal origin of cord blood autoantibodies was confirmed in a study of non-diabetic mothers [7] , but further studies on this matter are needed. In the offspring of mothers with type 1 diabetes, cord blood autoantibodies have been reported to increase the risk for development of diabetes in the child [10] , but also to have no effect [4] or even be protective [3] . In a retrospective case-control study of cord blood sera from children diagnosed before the age of 15 years, the presence of cord blood autoantibodies was reported to increase the risk of the child developing type 1 diabetes, even after excluding mothers with diabetes [10] . Unfortunately, no analysis of IA-2 was performed, with islet cell antibodies being used instead [10] . It cannot be excluded that IA-2A may have contributed to the risk of cord blood autoantibodies for type 1 diabetes in that study. A recent Danish study reported an increased risk of type 1 diabetes in children born with cord blood autoantibodies, but no separate analysis was performed for IA-2A and GADA [9] . One of the major strength of our analysis is that the data originate from a large-scale screening programme of the general population, with 70% of all children born in the Skåne region sampled at birth. Our data regarding the prevalence of type 1 diabetes in this cohort, now aged 9-13 years, are considered complete. The well-covered study area in Sweden, with five paediatric clinics and validation against the BDD study, minimises the risk of having missed new cases.
Our study is limited by reliance on questionnaire data regarding some pre-and perinatal factors. We can, therefore, assume that the data suffer from recall bias. Missing data from the 2-year questionnaire affect the number of patients eligible for multivariate analysis. However, we were still able to use data from 17,287 children and 89 type 1 diabetes patients. The number of children who were autoantibody-positive at birth was small, as was the number of children of mothers with type 1 diabetes. This introduces some uncertainty into the statistical analysis.
In conclusion, our study indicates that the presence of cord blood autoantibodies to IA-2, but not GADA or IAA, increases the risk of developing type 1 diabetes compared with the general population. The increased risk of maternal diabetes disappears after adjusting for IA-2A in cord blood, suggesting that IA-2A may be the primary risk factor. Further studies are needed to confirm this finding.
